No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes.

Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes' complications and additive detrimental liver outcomes.

The existence of a close association between NAFLD and hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes' complications and additive detrimental liver outcomes.

The existence of a close association between NAFLD and hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled trial.

Topics PubMed links to this paper include Cholecalciferol, Diabetes Mellitus, Type 2, Dietary Supplements, Italy, Non-alcoholic Fatty Liver Disease and Risk Factors.

Author keywords: NAFLD, Type 2 diabetes and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with fatty liver & elevated liver enzymes.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (BMC medicine), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.